All Stories

  1. Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events – a Canadian setting (DEVOTE 9)

    Article • Diabetes Obesity and Metabolism, March 2019, Wiley

    Mr Richard F Pollock

  2. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark

    Article • Advances in Therapy, November 2018, Springer Science + Business Media

    Mr Richard F Pollock

  3. Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach

    Article • Diabetes Metabolic Syndrome and Obesity, May 2018, Dove Medical Press

    Mr Richard F Pollock, Mr Barrie D Chubb

  4. An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland

    Article • ClinicoEconomics and Outcomes Research, April 2018, Dove Medical Press

    Mr Richard F Pollock

  5. Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States

    Article • Diabetes Therapy, March 2018, Springer Science + Business Media

    Mr Richard F Pollock

  6. Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness Evaluation

    Article • Applied Health Economics and Health Policy, March 2018, Springer Science + Business Media

    Mr Richard F Pollock

  7. Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden

    Article • Diabetes Therapy, December 2017, Springer Science + Business Media

    Mr Richard F Pollock

  8. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK

    Article • Expert Opinion on Drug Delivery, October 2017, Taylor & Francis

    Mr Richard F Pollock

  9. Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables

    Article • Journal of Medical Economics, October 2017, Taylor & Francis

    Mr Richard F Pollock

  10. A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000

    Article • ClinicoEconomics and Outcomes Research, August 2017, Dove Medical Press

    Mr Richard F Pollock

  11. The Prime Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus

    Article • Value in Health, July 2017, Elsevier

    Mr Richard F Pollock

  12. Patient safety during procedural sedation using capnography monitoring: a systematic review and meta-analysis

    Article • BMJ Open, June 2017, BMJ

    Mr Richard F Pollock

  13. Systematic Review and Meta-Analysis of Tacrolimus versus Ciclosporin as Primary Immunosuppression After Liver Transplant

    Article • PLoS ONE, November 2016, PLOS

    Mr Richard F Pollock

  14. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark

    Article • Journal of Medical Economics, October 2016, Taylor & Francis

    Mr Richard F Pollock

  15. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK

    Article • Journal of Medical Economics, June 2016, Taylor & Francis

    Mr Richard F Pollock

  16. Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US

    Article • Journal of Medical Economics, March 2016, Informa Healthcare

    Mr Richard F Pollock

  17. Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients

    Article • Advances in Therapy, February 2016, Springer Science + Business Media

    Mr Richard F Pollock

  18. Evaluating the Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice

    Article • Drugs - Real World Outcomes, January 2016, Springer Science + Business Media

    Mr Richard F Pollock

  19. A Cost-Utility Analysis of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus and Ciclosporin In Liver Transplant Recipients In The Uk

    Article • Value in Health, November 2015, Elsevier

    Mr Richard F Pollock

  20. Cost-Effectiveness of Rapid-Acting Analog Insulin for Type 1 Diabetes In The Uk Setting

    Article • Value in Health, November 2015, Elsevier

    Mr Richard F Pollock

  21. Evaluating The Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus In Liver Transplant Patients Based on Data From Routine Clinical Practice

    Article • Value in Health, November 2015, Elsevier

    Mr Richard F Pollock

  22. Verification and Validation of Health Economic Models for Diabetes

    Article • Value in Health, November 2015, Elsevier

    Mr Richard F Pollock

  23. Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK

    Article • Journal of Medical Economics, August 2015, Informa Healthcare

    Mr Richard F Pollock

  24. Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK

    Article • Diabetes Research and Clinical Practice, July 2015, Elsevier

    Mr Richard F Pollock

  25. An analysis of product wastage arising from dosing increment granularity in four modern growth hormone administration devices

    Article • Expert Opinion on Drug Delivery, January 2015, Informa Healthcare

    Mr Richard F Pollock

  26. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability

    Article • Journal of Medical Economics, May 2014, Informa Healthcare

    Mr Richard F Pollock

  27. Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence

    Article • Patient Preference and Adherence, March 2014, Taylor & Francis

    Mr Richard F Pollock, Mr Gorden Muduma

  28. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden

    Article • Journal of Medical Economics, October 2013, Informa Healthcare

    Mr Richard F Pollock

  29. Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis

    Article • Medical Devices Evidence and Research, August 2013, Taylor & Francis

    Mr Richard F Pollock

  30. Laparoscopic adjustable gastric banding vs standard medical management in obese patients with type 2 diabetes: a budget impact analysis in the UK

    Article • Journal of Medical Economics, December 2012, Informa Healthcare

    Mr Richard F Pollock

  31. A UK Analysis of the Cost-Effectiveness of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin

    Article • Advances in Therapy, November 2012, Springer Science + Business Media

    Mr Richard F Pollock

  32. Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK

    Article • Diabetes Obesity and Metabolism, September 2012, Wiley

    Mr Richard F Pollock

  33. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden

    Article • Journal of Medical Economics, May 2012, Informa Healthcare

    Mr Richard F Pollock

  34. A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States

    Article • Journal of Medical Economics, April 2012, Informa Healthcare

    Mr Richard F Pollock

  35. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands

    Article • Diabetic Medicine, February 2012, Wiley

    Mr Richard F Pollock

  36. A Review of the Cost Effectiveness of Bisphosphonates in the Treatment of Post-Menopausal Osteoporosis in Switzerland

    Article • Applied Health Economics and Health Policy, November 2011, Springer Science + Business Media

    Mr Richard F Pollock

  37. Long-Acting Insulin Analogs: A Review of “Real-World” Effectiveness in Patients with Type 2 Diabetes

    Article • Current Diabetes Reviews, January 2011, Bentham Science Publishers

    Mr Richard F Pollock

  38. The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective

    Article • Journal of Medical Economics, December 2010, Informa Healthcare

    Mr Richard F Pollock

  39. BioSAVE: Display of scored annotation within a sequence context

    Article • BMC Bioinformatics, March 2008, Springer Science + Business Media

    Mr Richard F Pollock